

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Bendele et al.

Serial No.:

09/907,263

Group Art Unit No.: 1646

Filed:

July 17, 2001

Examiner: E. O'Hara

For:

COMBINATION THERAPY USING A TNF BINDING

PROTEIN FOR TREATING TNF-MEDIATED

**DISEASES** 

RECEIVED

MAY 2 2 2003

Docket No.: A-430F

TECH CENTER 1600/2900

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 form and provides a copy of each of the listed references for consideration by the Examiner.

This Information Disclosure Statement is being filed after three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last, but before the mailing date of either:

- a final action under § 1.113 or (1)
- a notice of allowance under § 1.311, whichever occurs first.

## STATEMENT OR FEE

Acc	Accompanying this transmittal is:							
Α	a statement as specified in 37 CFR 1.97(e):							
	STATEMENT							
	I, the person(s) signing below state:							

**CERTIFICATE OF MAILING** 

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

160.00

			that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 CFR 1.97(e)(1).
			OR
	1		that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 CFR 1.97(e)(2).
			OR
B.	$\boxtimes$		fee set forth in 37 CFR 1.17(p) for submission of an information disclosure statement under 97(c). (\$180.00).
	Α	pplica	nts request consideration of this information and passage of the application to issue.

## **FEE PAYMENT**

Please charge Deposit Account No. 01-0519 in the amount of \$180.00 (37 CFR 1.97(c)). An original and one copy are enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519.

Respectfully submitted,

Timothy J. (au)
Attorney for Applicants

Registration No.: 33,111

Phone: (805) 447-2688 Date: May 15, 2003

Please send all future correspondence to: US Patent Operations/ TJG Dept. 4300, M/S 27-4-A AMGEN INC. One Amgen Center Drive Thousand Oaks, California 91320-1799

•		OIPE				Sheet	1 Of 1
	m PTO- 449	MAY 1 9 2003 B		Atty. Docket No. A-430F	Seria	al No	9/907,263
LIS	ST OF RE	FERENCES CHED BY		Applicant  Bendele et al.	•		
	(	(Use several dets if necessar	Filing Date July 17, 2001	Grou	ıp		
			U.S. PATENT	T DOCUMENTS			
EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A020	6,319,910	11/20/01	Amin et al.			
				ENT DOCUMENTS	*		
EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	TRANSLATION YES NO
	<del>                                     </del>						
					F	ECE	IVED
						MAY 2	<b>2</b> 2003
							<del></del>
	Į.				TEC	H CENH	<del>R 1600/29</del> 0
EXAMINER'S INITIALS		OTHER DOCUM	ENTS (Including	Author, Title, Date, Pert	inent Page	es, Etc.)	

EVALUED	
EXAMINER:	Date Considered:
	bate considered.
	l l
EVAMINED I SECTION AND ADDRESS OF THE PARTY	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.